Trial intelligence / Profile preview

TMC435 plus peginterferon alfa-2a and ribavirin in genotype 1 hepatitis C patients previously treated in placebo groups of earlier TMC435 trials

NL-OMON39317Phase 3Active, not recruiting

Sponsor

Tibotec

Start

Jan 2012

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1